ESR1 and breast carcinoma: Thus, while in early ESR1-positive breast cancer DC-SCRIPT inhibits progression of breast cancer, this effect appears to be neutralized in tumors high in ESR2. Indeed, ESR2 has been reported to be dominant over ESR1 and able to counteract the proliferation-inducing activities of ESR1 [1,2].